HOME >> BIOLOGY >> NEWS
A New Molecular Marker For Prostate Cancer

LOS ANGELES, June, 16, 1998 -- A new molecular marker can be used to better predict tumor progression in men with prostate cancer, the second-leading cause of male cancer deaths in the United States. Researchers at the USC/Norris Comprehensive Cancer Center report the new findings from a study of 96 men with localized disease in the June 17 issue of the Journal of the National Cancer Institute. The team found that patients with tumors expressing abnormally low levels of a protein important in regulating cell division faced a significantly higher risk of disease recurrence and death than patients with tumors expressing high levels of the protein.

"Physicians may be able to use this tumor marker to identify prostate cancer patients most likely to harbor dangerous, life-threatening tumors," says Richard J. Cote, M.D., who led the study team. Cote is an associate professor of pathology and urology at the USC/Norris Cancer Center.

"In addition, the marker can help doctors make better decisions about treatment, ensuring that men most likely to develop metastatic disease undergo aggressive therapies. It will also help identify men who can avoid the most intensive and expensive treatments," he says. The American Cancer Society estimates that this year 184,500 American men will be diagnosed with prostate cancer and that some 42,000 men will die of the disease. With one of the highest incidences of all cancers, it is the second-leading cause of cancer deaths in men. Gauging how aggressive prostate tumors are -- and thus how aggressive treatment should be -- has created a quandary for physicians and men diagnosed with early prostate cancer.

In the last decade, the widespread use of the prostate specific antigen (PSA) test has allowed the detection of many more cases of early prostate cancer than previously possible. Yet, scientists believe that many of the localized tumors identified by the PSA screen are so slow-growing that men are more likely to d
'"/>

Contact: Eva Emerson
eemerson@hsc.usc.edu
213-442-2830
University of Southern California
16-Jun-1998


Page: 1 2 3

Related biology news :

1. Molecular motor implicated in tissue remodeling
2. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
3. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
4. Molecular staples shape a cancer killer
5. Molecular motor myosin VI moves hand over hand, researchers say
6. Molecular therapeutics advance fight against brain cancer
7. Molecular motor shuttles key protein in response to light
8. Molecular traffic cop directs cellular signals
9. Molecular marker predicts success of breast cancer treatment
10. Molecular image of genotoxin reveals how bacteria damage human DNA
11. Molecular mechanism found that may improve ability of stem cells to fight disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/4/2020)... ... 03, 2020 , ... Aesthetics Biomedical (ABM), a leading aesthetics ... not only the products and treatments developed, but also the dedicated team behind ... the brands built by ABM have received several honors already for 2020, each ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... R&D, today announced that it has entered into a multi-year contract with ... to support their translational and clinical research strategy to discover and develop ...
(Date:6/23/2020)... ... June 22, 2020 , ... The field of quantitation of large ... (LBA) have dominated this area. However, the use of mass spectrometry in this field ... necessitates the question “How do you choose which approach to use (LBA or MS)?” ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... (PRWEB) , ... August 13, 2020 , ... True ... the creation of its Scientific Advisory Board (SAB) to research the medical potential of ... can be enhanced when combined with terpenes. The board is focused on expanding the ...
(Date:8/12/2020)... Mass. (PRWEB) , ... August 11, 2020 , ... ... $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research ... in 2021 and 2022. The network is a consortium of academic research centers ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 12, 2020 , ... ... Group, Inc. (EMMA International), a global leader in FDA compliance consulting has ... the nation’s fastest-growing private companies. The list represents a unique look at the ...
(Date:8/3/2020)... ... August 03, 2020 , ... ERT, the ... CEO has been named one of the 100 most inspiring individuals in the ... honorees are selected based on how they have inspired their colleagues and affected ...
Breaking Biology Technology:
Cached News: